---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-24-000271"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-06T00:07:22.245933+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexaria raises $3.6M in registered direct offering and private placement

## Summary
- Gross proceeds of ~$3.6M from issuance of 1,558,443 shares at $2.31/share and pre-funded warrants at $2.3099.
- Private placement issued unregistered warrants for up to 1,558,443 shares at $2.185 exercise price, 5-year term.
- Net proceeds earmarked for R&D studies, patent/legal costs, and general working capital.
- H.C. Wainwright acted as exclusive placement agent; fees equal 7% (6% for one investor) of gross proceeds plus agent warrants.
- Officers and directors subject to 30-day lock-up on common stock and equivalents post-closing.

## SEC filing metadata
- accession: 0001640334-24-000271
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000271/0001640334-24-000271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000271/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-24-000271
- JSON: https://secwatch.observer/filing/0001640334-24-000271.json
- Plain text: https://secwatch.observer/filing/0001640334-24-000271.txt

## Key facts
- Material Agreements
  Lexaria Bioscience Corp. entered into Engagement Agreement with H.C. Wainwright & Co., LLC (effective 2024-02-12).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: H.C. Wainwright & Co., LLC
  - Effective: 2024-02-12
  source text: In connection with the Offering, on February 12, 2024, the Company entered into an engagement agreement (the “Engagement Agreement”) with H.C. Wainwright & Co., LLC (the “Placement Agent”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000271/0001640334-24-000271-index.htm
- Material Agreements
  Lexaria Bioscience Corp. entered into securities purchase agreement with certain institutional investors valued at approximately $3.6 million (effective 2024-02-14).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: approximately $3.6 million
  - Effective: 2024-02-14
  source text: On February 14, 2024, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with certain institutional investors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000271/0001640334-24-000271-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.